✦ LIBER ✦

Randomised phase II/III study of docetaxel with or without risedronate in patients with metastatic Castration Resistant Prostate Cancer (CRPC), the Netherlands Prostate Study (NePro)

✍ Scribed by H.J. Meulenbeld; E.D. van Werkhoven; J.L.L.M. Coenen; G.J. Creemers; O.J.L. Loosveld; P.C. de Jong; A.J. ten Tije; S.D. Fosså; M. Polee; W. Gerritsen; O. Dalesio; R. de Wit

Book ID: 116431128
Publisher: Elsevier Science
Year: 2012
Tongue: English
Weight: 674 KB
Volume: 48
Category: Article
ISSN: 0959-8049
DOI: 10.1016/j.ejca.2012.05.014

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Randomized phase II study of danusertib

Randomized phase II study of danusertib in patients with metastatic castration-resistant prostate cancer after docetaxel failure

✍ Hielke J. Meulenbeld; Jean P. Bleuse; Elio M. Vinci; Eric Raymond; Giordano Vita 📂 Article 📅 2012 🏛 John Wiley and Sons 🌐 English ⚖ 245 KB

4025 POSTER A phase I/II study of suniti

4025 POSTER A phase I/II study of sunitinib in combination with docetaxel (dcx) and prednisone (pdn) in patients with metastatic castrate-resistant prostate cancer (mCRPC)

✍ A. Zurita; N.D. Shore; M.F. Kozloff; C.W. Ryan; T.M. Beer; E. Chow Maneval; I. C 📂 Article 📅 2007 🏛 Elsevier Science 🌐 English ⚖ 58 KB

Randomized, Double-Blind, Placebo-Contro

Randomized, Double-Blind, Placebo-Controlled Phase III Trial Comparing Docetaxel and Prednisone With or Without Bevacizumab in Men With Metastatic Castration-Resistant Prostate Cancer: CALGB 90401

✍ Kelly, W. K.; Halabi, S.; Carducci, M.; George, D.; Mahoney, J. F.; Stadler, W. 📂 Article 📅 2012 🏛 American Society of Clinical Oncology 🌐 English ⚖ 190 KB

Once-daily Dasatinib: Expansion of Phase

Once-daily Dasatinib: Expansion of Phase II Study Evaluating Safety and Efficacy of Dasatinib in Patients With Metastatic Castration-resistant Prostate Cancer

✍ Evan Y. Yu; Christophe Massard; Mitchell E. Gross; Michael A. Carducci; Stephane 📂 Article 📅 2011 🏛 Elsevier Science 🌐 English ⚖ 480 KB

Randomised phase II study of siltuximab

Randomised phase II study of siltuximab (CNTO 328), an anti-IL-6 monoclonal antibody, in combination with mitoxantrone/prednisone versus mitoxantrone/prednisone alone in metastatic castration-resistant prostate cancer

✍ K. Fizazi; J.S. De Bono; A. Flechon; A. Heidenreich; E. Voog; N.B. Davis; Ming Q 📂 Article 📅 2012 🏛 Elsevier Science 🌐 English ⚖ 336 KB

A randomized, dose–response, multicenter

A randomized, dose–response, multicenter phase II study of radium-223 chloride for the palliation of painful bone metastases in patients with castration-resistant prostate cancer

✍ S. Nilsson; P. Strang; A.K. Aksnes; L. Franzèn; P. Olivier; A. Pecking; J. Staff 📂 Article 📅 2012 🏛 Elsevier Science 🌐 English ⚖ 512 KB